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Abstract: NAD+-dependent histone deacetylases (sirtuins) are implicated in cellular processes such
as proliferation, DNA repair, and apoptosis by regulating gene expression and the functions of
numerous proteins. Due to their key role in cells, the discovery of small molecule sirtuin modulators
has been of significant interest for diverse therapeutic applications. In particular, it has been shown
that inhibition of sirtuin 1 and 2 activities is beneficial for cancer treatment. Here, we demonstrate
that the fungal metabolite eurochevalierine from the fungus Neosartorya pseudofischeri inhibits sirtuin
1 and 2 activities (IC50 about 10 µM) without affecting sirtuin 3 activity. The binding modes of the
eurochevalierine for sirtuin 1 and 2 have been identified through computational docking analyses.
Accordingly, this sequiterpene alkaloid induces histone H4 andα-tubulin acetylation in various cancer
cell models in which it induces strong cytostatic effects without affecting significantly the viability
of healthy PBMCs. Importantly, eurochevalierine targets preferentially cancer cell proliferation
(selectivity factor 7), as normal human primary CD34+ stem/progenitor cells were less affected
by the treatment. Finally, eurochevalierine displays suitable drug-likeness parameters and therefore
represent a promising scaffold for lead molecule optimization to study the mechanism and biological
roles of sirtuins and potentially a basis for development into therapeutics.
Keywords: cancer; epigenetics; HDAC; sirtuin inhibitor; natural compound; eurochevalierine;
cytostatic compound
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1. Introduction
The European Union [1] and the United States of America (USA) [2] as well as most developed
countries are facing an increasing health problem with respect to cancer. In the European Union, cancer
represents the second most important cause of death and morbidity with one out of four deaths [1]. In the
USA, about 1.7 millions new cancer cases and about 610,000 cancer deaths are projected for 2018 [2].
There is increasing evidence that, besides genetic lesions, epigenetic alterations including DNA
methylation, small non-coding RNAs, and histone modifications are regulating essential steps of
carcinogenesis [3–6]. Among the enzymes responsible for regulating epigenetic marks, histone
deacetylases (HDACs), the enzyme responsible for the removal of lysine acetyl groups, became
an interesting target for anti-cancer therapy [7,8]. There are 18 members in the HDAC family classified
into four major groups. Class I, II, and IV HDACs are zinc-dependent, whereas Class III HDACs,
also called sirtuins (SIRTs), require nicotinamide adenine dinucleotide (NAD+) as a co-factor [9,10].
Sirtuins (SIRT1-7) share extensive homologies with the yeast HDAC Silent Information Regulator 2
(Sir2). SIRT1 is essentially nuclear and modulates acetylation of histone H1, H3, and H4, whereas
SIRT2 is predominantly cytoplasmic and regulates α-tubulin, together with HDAC6 [11]. HDAC
inhibitors (HDACi) of class I, II, and IV are the most widely used for basic research as well as in the
clinic [12,13]; however, sirtuin inhibitors (SIRTi) represent a novel, attractive approach for anti-cancer
drug development [6,7]. Hence, numerous reports demonstrated that SIRT1, SIRT2, or dual SIRT1/2
inhibitors may generate anticancer effects. However, depending on the inhibitors and cancer cell
models, the observed antitumor effects and cellular outcomes are not always comparable and can be
mediated by various mechanisms [7]. For instance, the SIRT1/2 inhibitor sirtinol triggers growth arrest
in human breast and lung cancer cells [14]. Similarly, the benzopyran-based compound 18 inhibits
SIRT1/2 activities and acts as a cytostatic agent in glioblastoma cells [15], whereas the dual SIRT1/2
inhibitor tenovin-1 induces apoptosis in sarcoma cells [16]. Other specific sirtuin inhibitors (SIRTi)
have been reported to trigger cancer cell death, including the SIRT1 inhibitors NCO-01 and -04, and the
SIRT2 inhibitors AEM1 and AEM2, which induce cell death in T-cell leukemia/lymphoma [17] and in
non-small cell lung cancer [18], respectively. Nevertheless, several reports have demonstrated that
the knockdown of SIRT1, SIRT2, or SIRT1/2 genes affected less cancer cell viability but essentially
proliferation and/or invasion [19].
Natural products and their semisynthetic or synthetic derivatives represent more than 50%
of the current armamentarium to combat cancer [20–25]. Various natural compounds display
anti-HDAC activity [8,10,26] and the current study details the anti-HDAC activity of eurochevalierine,
a sequiterpene alkaloid (Figure 1), which is a fungal metabolite isolated from Eurotium chevalieri
Mangin that is an imperfect stage of Aspergillus chevalieri (Mangin) Thorn and Church and that belongs
to Phylum Ascomyceta [27]. We previously showed that eurochevalierine is a cytostatic but not cytotoxic
compound in vitro with respect to the growth of various cancer cell models [28]. Eurochevalierine
does not induce apoptosis in cancer cells and displays its cytostatic effects even in apoptosis-resistant
cancer cells [28].
Figure 1. Structure of eurochevalierine.
Molecules 2018, 23, 333 3 of 14
The aim of this work was to further investigate epigenetic regulatory mechanisms that could
account for the observed inhibition of cancer cell proliferation. Based on computational docking
experiments combined with in vitro HDAC activity assays and the examination of the profile of
acetylation of α-tubulin and several histone marks in various solid cancer models, we established that
eurochevalierine leads to specific inhibition of SIRT1 and 2.
2. Results
We previously published a series of secondary metabolites from Neosartorya pseudofischeri, among
which eurochevalierine (Figure 1) displayed interesting anti-cancer properties against multiple cell
lines of various origins [28]. More recently, another group further confirmed the relevant cytostatic
activity of eurochevalierine in glioblastoma and non-small cell lung cancer cells [29]. Accordingly,
in the current study, we sought to further investigate the anti-cancer properties of this sequiterpene
alkaloid. Although eurochevalierine displays cytostatic effects in various cancer models, we did
not observe eurochevalierine-induced modifications in the cell cycle distribution of cancer cells as
revealed by flow cytometry analyses. Nevertheless, a shift of the DNA histograms was observed in
eurochevalierine-treated A-549 cancer cells as if treated cells integrated more propidium iodide than
control cells (Figure 2A). DNA histogram analyses also revealed that eurochevalierine did not increase
the sub-G1 fraction in A-549 lung cancer, U-373 glioblastoma, or B16-F10 melanoma cells, even after
72 h of treatment with a concentration as high as 50 µM (Figure 2B), which nearly corresponds to two
times the mean IC50 value determined in a panel of cancer cell lines regarding growth inhibition [28].
These results confirmed that eurochevalierine does not behave as a cytotoxic compound and exerts its
anti-cancer activity via cytostatic properties.
Figure 2. Effect of eurochevalierine on cell cycle distribution. Cells were treated with 50 µM
eurochevalierine for 72 h and then stained with propidium iodide (PI), and DNA content was measured
by flow cytometry. (a) Cell cycle distribution profile in A-549 cells. Results of three independent
experiments are represented on the same graph. (b) Quantification of the number of cells in sub-G1
fraction as a percentage of the total cell population. Results are expressed as mean ± SD of at least
three independent experiments.
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Previous studies already revealed that the DNA conformation [30] and modifications in histone
H1 concentration [31] influences DNA stainability by propidium iodide as revealed by flow cytometry
analyses. It is well established that histone modifications including lysine acetylation and its
regulation by HDACs exert major roles in DNA structure [3,26,32]. Thus, we evaluated the effect of
eurochevalierine on in vitro HDAC activity. Eurochevalierine inhibited only about 33% of total HDAC
activity at a concentration of 100 µM (Figure 3A).
Figure 3. Eurochevalierine displays a moderate effect on in vitro non-sirtuin HDAC activities.
(a) In vitro total HDAC activity was evaluated using K-562 nuclear extracts in the presence of various
concentrations of eurochevalierine. (b) Selective in vitro HDAC activity assays were carried out using
selected recombinant HDAC proteins in the presence of various concentrations of eurochevalierine.
Results are reported as percent of DMSO vehicle control and expressed as the mean ± SD of three
independent experiments. * and ** indicate p < 0.05 and p < 0.01 versus untreated cells, respectively.
In order to determine whether this effect results from a weak inhibition of multiple HDAC
isoenzymes or a strong inhibition of a limited number of selected isoforms, we further tested the effect
of eurochevalierine on the deacetylase activity of selected HDAC members. At the concentration of
100 µM, eurochevalierine remained without effect on HDAC1, 2, 8, 10 and 11, inhibited about 36 and
51% of HDAC6 and 11 activities, respectively, and induced HDAC3 activity by 1.5-fold (Figure 3B).
Interestingly, eurochevalierine had IC50 values of 9.8 and 10 µM against SIRT1 and 2, respectively,
whereas it failed to reach the IC50 for SIRT3 at 100 µM (Table 1). Such values are comparable to the
one obtained with suramin used as a potent positive control for in vitro SIRT1 and SIRT2 inhibition
with IC50 values of 2.8 and 13 µM, respectively, and was inactive against SIRT3, which is in agreement
with previously published studies [33]. The natural SIRT inhibitor nicotinamide was also included
as a reference compound for in vitro SIRT3 inhibition [34]. Besides suramin, additional references
SIRT1/2, SIRT1, and SIRT2 inhibitors, namely, sirtinol, EX-527, and AGK2, respectively, performed in
a similar range or less efficiently [15].




Nicotinamide 2 97 ± 15 27 ± 3 67 ± 10
Suramin 3 2.8 ± 0.3 13 ± 1 >100 4
Sirtinol 3 82.5 ± 7.1 47.1 ± 4.0 ND
EX-527 3 0.10 ± 0.06 20.1 ± 4.2 ND
AGK2 3 98.1 ± 2.4 2.8 ± 1.0 ND
Eurochevalierine 9.8 ± 2.0 10.2 ± 3.9 >100 5
1 IC50 values represent the mean ± SD of three independent experiments. ND: not determined. 2 Nicotinamide was
use as in vitro reference SIRT3 inhibitor. 3 Suramin and sirtinol, EX-527, and AGK2 were used as in vitro reference
inhibitors of SIRT1/2, SIRT1, and SIRT2, respectively. Data from [15] obtained in the same experimental conditions.
4 70% and 5 59% are the remaining enzymatic activity at 100 µM compared to the control set to 100%.
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To further explore the potential of eurochevalierine as an SIRT inhibitor, we compared the docking
affinity between eurochevalierine and known reference inhibitors (sirtinol, EX-527, and AGK2) using
AutoDock Vina [35]. A carboxamide derivative and SirReal2 were used as control docking molecules
for SIRT1 and 2, respectively, to validate our docking experiments. The control docking results were
very close to the actual binding mode and the overall root-mean-square deviation (RMSD) values
between the actual binding mode and simulated docking pose of the carboxamide derivative on SIRT1
and of SirReal2 on SIRT2 were 1.3 Å and 0.4 Å, respectively (Supplementary Materials Figure S1).
Qualitative molecular docking experiments were performed with eurochevalierine in comparison with
sirtinol and EX-527 against three available human SIRT1 crystal structures that contain two static water
molecules in the binding site that would be influential both in the actual inhibition and in the docking
experiment [36,37]. The resulting lowest docking affinities are shown in Table 2.
Table 2. Qualitative molecular docking results of eurochevalierine against human SIRT1 1.
PDB_ID Eurochevalierine Sirtinol EX-527
4I5I −8.0 −9.0 −10.3
4ZZI −9.0 −10.8 −8.6
4ZZJ −9.0 −9.7 −8.9
Average −8.7 −9.8 −9.3
1 Binding affinity energy values (kcal/mol) with SIRT1 proteins in the indicated protein data bank (PDB) codes.
Sirtinol and EX-527 were used as reference inhibitors of SIRT1/2 and SIRT1, respectively.
In Figure 4a, the docking pose of eurochevalierine with the lowest binding affinity was selected as
the most favorable binding mode in the binding pocket of SIRT1 [PDB code 4ZZI], and the carboxamide
derivative, the inhibitor in the original SIRT1 crystal structure, was superposed for comparison [37].
Even though the binding affinity for eurochevalierine was higher than two reference molecules, sirtinol
and EX-527, eurochevalierine was predicted to interact with SIRT1 primarily through hydrophobic
effects and to occupy the hydrophobic cage formed by residues Ala262, Phe273, Phe297, Ile347, Ile411,
Val412, Phe413, and Phe414, as the control molecule binds to SIRT1. Notably, eurochevalierine exhibits
pi–pi stacks with the side chain of Phe273 like the carboxamide derivative.
Figure 4. Cont.
Molecules 2018, 23, 333 6 of 14
Figure 4. Eurochevalierine docked into human SIRT1 and SIRT2. (a) Docking pose of eurochevalierine
on the crystal structure of SIRT1 (bright orange; PDB code 4ZZI). The carboxamide derivative
(light magenta), the inhibitor in the original SIRT1 crystal structure, was superposed. (b) Docking
pose of eurochevalierine on the crystal structure of SIRT2 (green; PDB code 4RMH). SirReal2 (yellow),
the inhibitor in the original SIRT2 crystal structure, was superposed. Close-up views on the right show
that eurochevalierine (cyan) binds to the active site of the SIRT1 and 2 structures. The residues involved
in hydrophobic effects with eurochevalierine are represented as gray-colored sticks. Static water
molecules are shown as yellow dots.
In addition, similar docking experiments were performed with eurochevalierine in comparison
with sirtinol and AGK2 against three available human SIRT2 crystal structures that contain one static
water molecule in the binding site [38,39]. The resulting lowest docking affinities are shown in Table 3.
The calculated binding affinity could not correlate our experimental data, such as the IC50 values in all
aspect, which is mainly caused by the limitation of qualitative docking simulations such as protein
flexibility, water/buffer treatments, and the less specific prediction of hydrophobic effects. In Figure 4b,
the docking pose of eurochevalierine with the lowest binding affinity was selected as the most favorable
binding mode in the binding pocket of SIRT2 (PDB code 4RMH), and SirReal2, the inhibitor in the
original SIRT2 crystal structure, was superposed for comparison [38]. Eurochevalierine was predicted
to occupy the pocket adjacent to the NAD+-binding site like SirReal2 (ref. accession number: 25672491)
and to interact with SIRT2 primarily through hydrophobic effects stabilized by the hydrophobic cage
(residues Phe96, Ile118, Phe119, Phe131, Ala135, Leu138, Tyr139, Pro140, Phe143, Ile169, Phe190, Ile232,
Val233, and Phe234).
Table 3. Qualitative molecular docking results of eurochevalierine against human SIRT2 1.
PDB_ID Eurochevalierine Sirtinol AGK2
4RMG −9.0 −10.2 −11.2
4RMH −10.0 −9.1 −11.8
5DY4 −9.1 −10.4 −10.9
Average −9.4 −9.9 −11.3
1 Binding affinity energy values (kcal/mol) with SIRT2 proteins in the indicated PDB codes. Sirtinol and AGK2
were used as reference inhibitors of SIRT1/2 and SIRT2, respectively.
To assess the HDAC inhibitory activity of eurochevalierine in cellulo, we analyzed the acetylation
status of SIRT1 and 2 substrates including histone H4, histone H3 at lysine 56 and α-tubulin in
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SK-MEL-28, U-373, and A-549 cell lines. Since suramin, an SIRT1 and 2 inhibitor reported in the
literature, failed to induce any increase in histone or α-tubulin acetylation in our models (Figure S2),
cells treated with the pan-HDACi suberoylanilide hydroxamic acid (SAHA) served as a positive
control for the induction of protein acetylation. Eurochevalierine induced a robust and dose-dependent
increase in the acetylation of sirtuin targets (Figure 5), in agreement with the in vitro inhibition of
SIRT1 and 2 activities.
Figure 5. Effect of eurochevalierine on the acetylation status of sirtuin targets. SK-MEL-28, U-373,
and A-549 cells were treated with 5 and 50 µM eurochevalierine (EU) for 8 h. Acetylation of histone H4
(AcH4), histone H3 at lysine 56 (AcH3K56), and α-tubulin (Ac α-tubulin) was analyzed via Western
blot. β-actin and histone H1 were used as loading controls for the analysis of total and acid extracts,
respectively. SAHA (S, 1 µM) was used as a reference HDAC inhibitor. Blots are representative of three
independent experiments.
As a potential candidate for further anti-cancer drug development, we then evaluated the
biological activity of eurochevalierine in healthy cell models. First, we tested the effect of
eurochevalierine on the viability of peripheral blood mononuclear cells (PBMCs) from healthy donors
treated for up to 48 h. Results (Figure 6) revealed that eurochevalierine does not trigger any acute
toxicity on this model even at a concentration of 100 µM.
Figure 6. Eurochevalierine does not alter the viability of normal cells. The viability of PBMCs
from healthy donors was assessed after 24 and 48 h of treatment at the indicated concentration
of eurochevalierine. Results correspond to mean ± SD of three independent experiments.
Since eurochevalierine exerts its anti-cancer activity as a cytostatic agent, we further tested the
impact of this natural compound on a proliferating healthy cell model represented by primary human
CD34+ stem/progenitor cells. We observed a maximum growth inhibition of around 30% (Figure 7A)
upon 200 µM eurochevalierine even after 72 h of treatment associated with a minor impact on cell
viability (Figure 7B). Considering that the mean IC50 value for the growth inhibition of cancer cells
is 28 µM [28], and that, in health cells, a concentration of 200 µM is not sufficient to reach the IC50
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(Figure 7A), eurochevalierine displays an important selective toxicity (factor >> 7) for cancer cells
compared to normal proliferating cells.
Figure 7. Only very high concentrations of eurochevalierine impair the growth of healthy primary
human CD34+ stem/progenitor cells. CD34+ cells were incubated with the indicated concentrations of
eurochevalierine and cell growth (a) and viability (b) were assessed after 72 h of treatment. Results
correspond to the mean ± SD of three independent experiments with * and ** indicate p < 0.05 and
p < 0.01 versus control.
Finally, we wanted to evaluate the drug-likeness properties of eurochevalierine in comparison to
other reference SIRTi. Accordingly, we checked whether compounds obey to the extended “rule of five”
[molecular weight comprised between 180 and 500 kDa, miLogP≤ 5, rotatable bonds≤ 10, topological
polar surface area (TPSA) ≤ 140, hydrogen-bond donors ≤ 5 and hydrogen-bond acceptors ≤ 10)
combined to an in silico assessment of ADMET (absorption, distribution, metabolism, elimination,
and toxicity)] properties (Table 4 and Table S1).
Table 4. In silico drug-likeness parameters calculated for reference sirtuin inhibitors (SIRTi)
and eurochevalierine.
Method Parameter 1 Values
Theoretical Eu Suramin Nicotinamide Sirtinol EX-527 AGK2
Rule of 5 n-atoms 20 ≤ x ≤ 70 38 86 9 30 17 30
MW (KDa) 180 ≤ x ≤ 500 526.63 1297.3 122.13 394.47 248.71 434.28
miLogP ≤5 4.04 −5.72 −0.48 5.67 2.51 5.73
TPSA ≤140 131.03 483.74 55.99 61.69 58.88 78.92
n-ON ≤10 9 29 3 4 3 5
n-OHNH ≤5 3 12 2 2 3 1
n-rotb ≤10 11 16 1 5 1 4
Absorption BBBP 0.1 ≤MA ≤ 2 0.10 0.04 0.34 3.10 4.10 0.08
IA ≥70% 92.6 65.2 93 95.8 90.3 97.3
PPB <90% 84.8 100 2.03 91.1 91.0 97.5
Toxicity Rat NA Negative Negative Negative Negative Negative Positive
Cardiac NA Ambigous Ambigous Medium Ambigous Medium Medium
1 BBBP: blood-brain barrier penetration; IA: intestinal absorption; miLogP: octanol-water partition coefficient;
MW: molecular weight; n-atoms: number of atoms; n-OHNH: number of hydrogen bond donors; n-ON: number
of hydrogen acceptors; n-rotb: number of rotatable bonds; PPB: plasma protein binding; TPSA: topological polar
surface area. EU: eurochevalierine; MA: middle absorption; NA: not applicable.
Collectively, such predictive analyses indicate that eurochevalierine is a suitable drug candidate
with more favorable parameters compared with other reference SIRT inhibitors, exhibiting high
probability of good oral bioavailability and absorption and a low risk of toxicity. Indeed, the number of
rotatable bonds in the eurochevalierine molecule, which defines the molecular flexibility for membrane
permeation, was just above the defined limit, and the favorable topological polar surface area, which
predicts drug transport properties, is in agreement with a favorable intestinal absorption parameter
(92.6%). Unlike eurochevalierine, other compounds such as sirtinol, EX-527, and AGK2 display
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an unfavorable plasma protein binding potential, which predicts a reduced bio-availability of these
compounds. Furthermore, the bio-availability of sirtinol and AGK2 might be further limited due to the
high lipophilicity (i.e., high miLogP value). Suramin is a very large molecule with very unfavorable
drug-likeness parameters.
3. Discussion
It is well accepted that sirtuins play an essential role in cancer cell proliferation and metabolism
as well as in aging and inflammation processes [40]. Therefore, modulating sirtuin activities could
have therapeutic value. For instance, upregulation of SIRT1 has been reported in multiple cancer cell
lines, indicating that SIRT1 inhibitor may be useful as therapeutic agents. Furthermore, non-sirtuin
HDACi as well as SIRT2 inhibitors may be of interest to reduce neurodegenerative processes [40].
Here, we identified that the sequiterpene alkaloid eurochevalierine displays a selective sirtuin 1/2
inhibitory profile, which provide a novel chemical scaffold for the lead compound development of
SIRT1- and 2-based cancer therapy. Nonetheless, the type of inhibition (i.e., reversible or irreversible)
and mechanism (e.g., competitive or noncompetitve) remains to be investigated.
Suramin, originally used for the treatment of trypanosomiasis and onchocerciasis, was described
as a potent in vitro SIRTi (SIRT1, 2, and 5) [41]. Accordingly, this symmetric polyanionic naphthylurea
compound is frequently used as a positive control for in vitro sirtuin activity assays; however, to the
best of our knowledge there is no report attesting to the capacity of suramin to trigger increased lysine
acetylation of sirtuin targets. Conversely, we showed in this study that suramin failed to increase the
acetylation level of two well characterized sirtuin targets (Figure S2). These results could be explained
by the incapacity of suramin to reach in cellulo its cytoplasmic and/or nuclear sirtuin targets due to
its relatively high molecular weight or by its inactivation through metabolic transformation. Such
hypothesis is in agreement with the unfavorable predicted parameters for suramin drug-likeness
(Table 4). In contrast, eurochevalierine was able to inhibit SIRT1 and 2 activities in vitro with IC50
values in the same range as suramin but also to induce the acetylation of a cytosolic (α-tubulin) as well
as a nuclear target (histone H4) of SIRTs. Furthermore, eurochevalierine appears as a suitable drug
candidate with more favorable parameters compared to the other tested reference SIRTi.
Sirtinol [42] as well as cambinol [43] described as selective SIRT1 and 2 inhibitors were previously
described to act as potent anti-inflammatory agents. Further study suggested that the anti-cancer
properties of sirtinol are linked to decreased proliferation capacities mediated by the development
of a senescence-like growth arrest phenotype in human breast cancer MCF-7 and lung cancer H1299
cells [14]. Remarkably, Peck et al. reported that the SIRT1 and 2 inhibitors sirtinol, nicotinamide,
and salermide decrease proliferation of cancer cells without affecting cell cycle distribution as observed
here with eurochevalierine (Figure 2A), whereas the SIRT1-specific inhibitor EX-527 triggers G1 cell
cycle arrest [44]. Similarly, AK-1, a specific SIRT2 inhibitor, induces G1 cell cycle arrest via the
upregulation of p21 in colon HT29 cells [45,46]. Recently, it has been shown that EX-527 and AGK2
decrease Hela cervical cancer cell proliferation associated with G1 phase arrest and the downregulation
of CDK4 and/or CDK6 [47]. Moreover, effects leading to increased α-tubulin acetylation and
modulation of microtubule dynamics and architecture could also contribute to impaired mitosis
and proliferation [11]. Altogether these results indicate that the inhibition of SIRT1 and SIRT2 activities
by eurochevalierine may account for its cytostatic anti-cancer properties observed previously [28].
It should be noted that eurochevalierine also exhibited inhibitory effects against HDAC6 and
11 activities, albeit at higher concentrations. Considering the major role of HDAC6 in regulating
many cellular processes and its implication in cancer progression, over the past few years, HDAC6
has emerged as an attractive pharmacological target, whose inhibition alone or in combination
treatments displays promising anti-cancer properties in various cancer subtypes including multiple
myeloma [8,48]. Thus, we cannot rule out the possibility that these combinational inhibitory effects
may contribute to the selective anti-cancer properties of eurochevalierine.
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4. Materials and Methods
4.1. Compounds
Eurochevalierine was isolated from solid culture of Neosartorya pseudofischeri according to
a procedure previously published [49]. Eurochevalierine, nicotinamide (Sigma, Bornem, Belgium),
suramin (Sigma), and SAHA (Cayman, Bio-connect, Huissen, The Netherlands) were dissolved
in DMSO.
4.2. Cell Culture and Viability Assay
Cancer cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA,
USA), from the European Collection of Cell Culture (ECACC; Salisbury, UK), and from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Brauschweig, Germany). These cell lines
include the human SK-MEL-28 melanoma (ATCC code HTB-72), the U-373 glioma (ECACC code
08061901), the A-549 non-small-cell lung cancer (DSMZ code ACC107), the K-562 chronic myeloid
leukemia (DSMZ code ACC10), and the murine B16-F10 melanoma (ATCC code CRL-6475) models.
PBMCs were isolated as previously reported [50].
Primary CD34+ progenitor/stem cells were isolated from human umbilical cord blood obtained
from the Clinique Bohler (Hôpitaux Robert Schuman, Luxembourg, Luxembourg) with the written
informed consent of parents with the approval of the National Research Ethics Committee of
Luxembourg. First, mononucleated cells were isolated by Ficoll™ (GE Healthcare, Roosendaal,
The Netherlands) density gradient centrifugation. CD34+ cells were then purified out from
mononucleated cells using magnetic cell sorting following the manufacturer’s instructions (MACS
Miltenyi, Utrecht, The Netherlands).
High purity CD34+ cells were treated after 3 days of amplification in Stemline® II Hematopoietic
Stem cell Expansion Medium (Sigma) supplemented with 1% antibiotic-antimycotic (BioWhittaker®,
Lonza, Verviers, Belgium), 4 mM L-glutamine (BioWhittaker®), 50 ng/mL stem cell factor (ReliaTech,
Wolfenbüttel, Germany), and 10 ng/mL interleukin 3 (Reliatech, Wolfenbüttel, Germany). Other cell
models were cultured in RPMI1640 (BioWhittaker®) supplemented with 10% heat-inactivated fetal calf
serum (BioWhittaker®) and 1% antibiotic-antimycotic. Cell lines were cultured at 37 ◦C in a humid
atmosphere and at 5% CO2.
PBMCs and CD34+ cells were processed through a semi-automated image-based cell analyzer
(Cedex XS Innovatis, Roche, Luxembourg), which provides information about cell concentration and
viability based on the Trypan Blue exclusion method.
4.3. Flow Cytometry
Cells were collected, fixed, and stained with the APO AF TUNEL detection kit (BD, Erembodegem,
Belgium) allowing analysis of both apoptosis and cell cycle at the same time [28]. The experiment
was conducted accordingly to the procedure of the manufacturer. Data were obtained through flow
cytometry with a Cell Lab Quanta apparatus (Analis, Suarlee, Belgium).
4.4. In Vitro HDAC Activity Assay
HDAC assays were carried out as previously described [51].
4.5. Docking Studies
Docking studies were performed as previously described [15] with a docking grid size of
25 Å × 25 Å × 25 Å, which encompassed the entire inhibitor binding pocket of SIRT1 and 2 structures.
To prepare the SIRT coordinates for docking simulation, ligands and all water molecules were removed
except static water molecules in the binding site that could play important roles in the actual inhibition.
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4.6. Protein Extraction and Western Blotting
Total proteins were extracted using the MPER® reagent (Thermo-scientific, Erembodegem-Aalst,
Belgium) supplemented by 1× protease inhibitor cocktail (Complete EDTA-free, Roche, Prophac,
Luxembourg, Luxembourg) according to manufacturer’s instructions. Histones were extracted as
previously described [52]. Western blots were carried out as previously reported [53].
Anti-acetylated α-tubulin (sc-23950) was from Santa Cruz Biotechnology (Tebubio, Boechout,
Belgium); anti-acetylated histone H4 (06-866), anti-acetylated histone H3 lysine 56 (04-1135),
anti-histone H1 (05-457) were from Millipore (Brussels, Belgium); anti-β-actin (A5441) was from
Sigma. Corresponding secondary antibodies were from Santa Cruz Biotechnology.
4.7. Calculation of Drug-Like Properties
Important molecular properties to predict the drug-likeness of a compound were computed using
the web-based Molinspiration [54] and PreADMET ver 2.0 [55] programs.
4.8. Statistics
Statistical analyses were carried out using the GraphPad Prism 6.0 software (GraphPad Software,
La Jolla, CA, USA). One-way ANOVA followed by the Holm–Sidak multiple comparison tests were
used for statistical comparisons. p-values less than 0.05 were considered statistically significant.
Supplementary Materials: The following are available online; Figure S1: Control docking results; Figure S2:
Suramin fails to induce histone H4 or α-tubulin acetylation in K-562 cells; Table S1: Global drug-likeness
parameters calculated for reference sirtuin inhibitors and eurochevalierine.
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